Related references
Note: Only part of the references are listed.Emerging drugs for cystic fibrosis
Reshma Amin et al.
EXPERT OPINION ON EMERGING DRUGS (2014)
Lung disease modifier genes in cystic fibrosis
Loic Guillot et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2014)
Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function
Fredrick Van Goor et al.
JOURNAL OF CYSTIC FIBROSIS (2014)
Revertant mutants modify, but do not rescue, the gating defect of the cystic fibrosis mutant G551D-CFTR
Zhe Xu et al.
JOURNAL OF PHYSIOLOGY-LONDON (2014)
Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis
Deborah M. Cholon et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Synergy-Based Small-Molecule Screen Using a Human Lung Epithelial Cell Line Yields ΔF508-CFTR Correctors That Augment VX-809 Maximal Efficacy
Puay-Wah Phuan et al.
MOLECULAR PHARMACOLOGY (2014)
Corrector VX-809 stabilizes the first transmembrane domain of CFTR
Tip W. Loo et al.
BIOCHEMICAL PHARMACOLOGY (2013)
GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit
Sander Pronk et al.
BIOINFORMATICS (2013)
Revertants, Low Temperature, and Correctors Reveal the Mechanism of F508del-CFTR Rescue by VX-809 and Suggest Multiple Agents for Full Correction
Carlos M. Farinha et al.
CHEMISTRY & BIOLOGY (2013)
VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1
Hong Yu Ren et al.
MOLECULAR BIOLOGY OF THE CELL (2013)
Mechanism-based corrector combination restores ΔF508-CFTR folding and function
Tsukasa Okiyoneda et al.
NATURE CHEMICAL BIOLOGY (2013)
A functional CFTR assay using primary cystic fibrosis intestinal organoids
Johanna F. Dekkers et al.
NATURE MEDICINE (2013)
Managing the Underlying Cause of Cystic Fibrosis: A Future Role for Potentiators and Correctors
Luis J. V. Galietta
PEDIATRIC DRUGS (2013)
Cystic Fibrosis Transmembrane Regulator Correctors and Potentiators
Steven M. Rowe et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2013)
Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved Sequences
Juan L. Mendoza et al.
CELL (2012)
Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and Function
Wael M. Rabeh et al.
CELL (2012)
Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
Patrick A. Flume et al.
CHEST (2012)
Ivacaftor potentiation of multiple CFTR channels with gating mutations
Haihui Yu et al.
JOURNAL OF CYSTIC FIBROSIS (2012)
Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia
Guido Veit et al.
MOLECULAR BIOLOGY OF THE CELL (2012)
Ivacaftor
Pamela B. Davis et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells
Frank A. Suprynowicz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
J. P. Clancy et al.
THORAX (2012)
MicroRNAs and cystic fibrosis - an epigenetic perspective
Wenming Xu et al.
CELL BIOLOGY INTERNATIONAL (2011)
Cystic Fibrosis Transmembrane Conductance Regulator Intracellular Processing, Trafficking, and Opportunities for Mutation-Specific Treatment
Mark P. Rogan et al.
CHEST (2011)
Potent, Metabolically Stable Benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR Inhibitors for Polycystic Kidney Disease
David S. Snyder et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Bonnie W. Ramsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Inhibition of Ca2+-activated Cl- channels by gallotannins as a possible molecular basis for health benefits of red wine and green tea
Wan Namkung et al.
FASEB JOURNAL (2010)
The Cystic Fibrosis-causing Mutation ΔF508 Affects Multiple Steps in Cystic Fibrosis Transmembrane Conductance Regulator Biogenesis
Patrick H. Thibodeau et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Quality control for unfolded proteins at the plasma membrane
Pirjo M. Apaja et al.
JOURNAL OF CELL BIOLOGY (2010)
CFTR-Adenylyl Cyclase I Association Responsible for UTP Activation of CFTR in Well-Differentiated Primary Human Bronchial Cell Cultures
Wan Namkung et al.
MOLECULAR BIOLOGY OF THE CELL (2010)
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation
Frank J. Accurso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Primary Folding Defect and Rescue of ΔF508 CFTR Emerge during Translation of the Mutant Domain
Hanneke Hoelen et al.
PLOS ONE (2010)
Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide-binding domain 1
Irina Protasevich et al.
PROTEIN SCIENCE (2010)
Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane
Tsukasa Okiyoneda et al.
SCIENCE (2010)
AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility
Garrett M. Morris et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2009)
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
CFTR function and prospects for therapy
John R. Riordan
ANNUAL REVIEW OF BIOCHEMISTRY (2008)
Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function
Adrian W. R. Serohijos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials
Michael Wilschanski et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
The role of cystic fibrosis transmembrane conductance regulator phenylalanine 508 side chain in ion channel gating
L Cui et al.
JOURNAL OF PHYSIOLOGY-LONDON (2006)
Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o-
C Ehrhardt et al.
CELL AND TISSUE RESEARCH (2006)
Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening
N Pedemonte et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Mechanisms of disease: Cystic fibrosis
SM Rowe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
CFTR gating - II: Effects of nucleotide binding on the stability of open states
SG Bompadre et al.
JOURNAL OF GENERAL PHYSIOLOGY (2005)
Impact of the ΔF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure
HA Lewis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The F508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR
K Du et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2005)
ModLoop: automated modeling of loops in protein structures
A Fiser et al.
BIOINFORMATICS (2003)
Nanomolar affinity small molecule correctors of defective ΔF508-CFTR chloride channel gating
H Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator ΔF508
ACV deCarvalho et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Two mechanisms of genistein inhibition of cystic fibrosis transmembrane conductance regulator Cl- channels expressed in murine cell line
KA Lansdell et al.
JOURNAL OF PHYSIOLOGY-LONDON (2000)
Share Paper
